Zoetis Inc. $ZTS Position Reduced by Ritholtz Wealth Management

Key Points

• Ritholtz Wealth Management cut its Zoetis stake by 55.8% in Q4, selling 10,865 shares and leaving 8,619 shares worth about $1.08 million, while institutional investors collectively own roughly 92.8% of the company.
• Analyst sentiment is mixed with a consensus rating of Hold and a $152.91 target; recent moves include a Weiss downgrade to "sell," Piper Sandler trimming its price target to $135, and a split of 6 Buy / 7 Hold / 1 Sell among analysts.
• Zoetis beat Q4 estimates (EPS $1.48 vs. $1.40; revenue $2.39B vs. $2.36B), set FY2026 guidance of 7.00–7.10 EPS, trades near $121 with a ~$50.9B market cap, and pays a $0.53 quarterly dividend (≈1.8% yield).

Ritholtz Wealth Management lowered its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 55.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,619 shares of the company's stock after selling 10,865 shares during the period. Ritholtz Wealth Management's holdings in Zoetis were worth $1,084,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of ZTS. Halbert Hargrove Global Advisors LLC lifted its holdings in shares of Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company's stock valued at $25,000 after purchasing an additional 144 shares in the last quarter. Global Wealth Strategies & Associates purchased a new stake in shares of Zoetis in the fourth quarter valued at $25,000. Lodestone Wealth Management LLC purchased a new stake in shares of Zoetis in the fourth quarter valued at $30,000. KERR FINANCIAL PLANNING Corp purchased a new stake in shares of Zoetis in the third quarter valued at $31,000. Finally, Holos Integrated Wealth LLC purchased a new stake in shares of Zoetis in the fourth quarter valued at $32,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on ZTS shares. Weiss Ratings lowered shares of Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Friday, March 27th. Piper Sandler reissued a "neutral" rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Wall Street Zen raised shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Saturday, February 21st. William Blair reissued an "outperform" rating on shares of Zoetis in a research report on Monday, March 2nd. Finally, Leerink Partners reissued a "market perform" rating on shares of Zoetis in a research report on Tuesday, March 10th. Six investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Zoetis presently has an average rating of "Hold" and a consensus target price of $152.91.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $121.11 on Wednesday. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a 1 year low of $113.29 and a 1 year high of $172.23. The business has a fifty day simple moving average of $122.10 and a 200 day simple moving average of $126.74. The firm has a market cap of $50.94 billion, a price-to-earnings ratio of 20.12, a P/E/G ratio of 1.83 and a beta of 0.98.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis's quarterly revenue was up 3.0% compared to the same quarter last year. During the same period last year, the company earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis's dividend payout ratio (DPR) is presently 35.22%.

Zoetis Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.